BIOCRYST PHARMACEUTICALS INC (BCRX)

Nasdaq Biotechnology Diagnostics SIC: 2836
A+
Pipeline Grade

Financial Position (from SEC Filings)

$173.4M
Cash & Equivalents
$61.8M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$2,318M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (2 Assets)

DrugPhaseIndications
PERAMIVIR
RAPIVAB 		APPROVED Acute, Uncomplicated Human Influenza, Arthritis, B-cell Acute Lymphoblastic Leukemia, Cancer, Chronic Lymphocytic Leukemia (CLL), Complement 3 Glomerulopathy, Cough, COVID-19, Cutaneous T-cell Lymphoma (CTCL),, Diabetic Macular Edema (DME), Ebola Virus Infection, Fatigue, Fever, Filovirus Infections, Gout, HAE, Headache, Hereditary Angioedema, Hereditary Angioedema (HAE), HIV Infections, Hyperuricemia, Immunoglobulin A Nephropathy, Influenza, Joint Disease, Leukemia, Leukemia, Lymphocytic, Leukemia, Lymphocytic, Chronic, Leukemia, T-Cell, Lymphoma, Marburg Virus Disease, Membranous Nephropathy, Myalgia, Nasal Congestion, Netherton Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pediatric, PNH, Prophylaxis, Renal Failure, Renal Insufficiency, Seasonal Influenza, Sore Throat, Yellow Fever
BEROTRALSTAT DIHYDROCHLORIDE
ORLADEYO 		APPROVED —

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BCRX.

SEC EDGAR Filings

All SEC filings for BIOCRYST PHARMACEUTICALS INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.